Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Apr 26, 2023

Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

See More Press Releases

The Conversation (0)

Alert Options

No alert set

INN Article Notification

Instant Daily Weekly

Alert Option

You will be notified when this event occurs. No additional settings needed.